View Post

KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC

In In The News by Barbara Jacoby

By: Joyce A. O’Shaughnessy, MD, Sara A. Hurvitz, MD From: Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer. Transcript: Joyce A. O’Shaughnessy, MD: Let’s go on to the third data set, which is the KEYNOTE-522. We’re finally getting a big advance for patients with high-risk TNBC [triple-negative breast cancer] in …